We demonstrate that FASN inhibition monotherapy of patients with NASH leads to increases in PUFA TAG composition after 12 weeks of oral administration highlighting that the described mechanism is applicable to disease states. Here, FASN is linked to metabolic dysfunction-associated steatohepatitis.